These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1328 related items for PubMed ID: 19019834

  • 1. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 2. Chronic heart failure: an overview of conventional treatment versus novel approaches.
    Landmesser U, Drexler H.
    Nat Clin Pract Cardiovasc Med; 2005 Dec 15; 2(12):628-38. PubMed ID: 16306919
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.
    Yoshiyama M, Nakamura Y, Omura T, Izumi Y, Matsumoto R, Oda S, Takeuchi K, Kim S, Iwao H, Yoshikawa J.
    Heart; 2005 Aug 15; 91(8):1080-5. PubMed ID: 16020603
    [Abstract] [Full Text] [Related]

  • 4. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X, Saini HK, Wang J, Gupta SK, Goyal RK, Dhalla NS.
    Expert Rev Cardiovasc Ther; 2005 Jul 15; 3(4):717-32. PubMed ID: 16076281
    [Abstract] [Full Text] [Related]

  • 5. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD, Udelson JE, Konstam MA.
    Curr Opin Cardiol; 1998 May 15; 13(3):162-7. PubMed ID: 9649938
    [Abstract] [Full Text] [Related]

  • 6. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
    Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J.
    Circulation; 2008 Aug 19; 118(8):818-27. PubMed ID: 18678774
    [Abstract] [Full Text] [Related]

  • 7. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.
    Udelson JE, Konstam MA.
    J Card Fail; 2002 Dec 19; 8(6 Suppl):S465-71. PubMed ID: 12555159
    [Abstract] [Full Text] [Related]

  • 8. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS.
    Minerva Cardioangiol; 2003 Apr 19; 51(2):143-54. PubMed ID: 12783070
    [Abstract] [Full Text] [Related]

  • 9. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN.
    Clin Cardiol; 1999 Oct 19; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [Abstract] [Full Text] [Related]

  • 10. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 19; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 11. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan 19; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 12. Drugs for left ventricular remodeling in heart failure.
    Frigerio M, Roubina E.
    Am J Cardiol; 2005 Dec 19; 96(12A):10L-18L. PubMed ID: 16399088
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
    Makino T, Hattori Y, Matsuda N, Onozuka H, Sakuma I, Kitabatake A.
    J Pharmacol Exp Ther; 2003 Jan 19; 304(1):370-9. PubMed ID: 12490614
    [Abstract] [Full Text] [Related]

  • 14. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 19; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 15. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z, Rogers JG.
    Curr Opin Cardiol; 2009 May 19; 24(3):223-9. PubMed ID: 19318933
    [Abstract] [Full Text] [Related]

  • 16. New concepts in post-infarction ventricular remodeling.
    Udelson JE, Patten RD, Konstam MA.
    Rev Cardiovasc Med; 2003 May 19; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [Abstract] [Full Text] [Related]

  • 17. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 19; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 18. Optimal management of chronic heart failure in patients with chronic kidney disease.
    Zachariah D, Kalra PA, Kalra PR.
    J Ren Care; 2009 Mar 19; 35(1):2-10. PubMed ID: 19200271
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 20. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.